Soleno Therapeutics – Consensus Indicates Potential 344.6% Upside

Broker Ratings

Soleno Therapeutics with ticker code (SLNO) have now 3 analysts covering the stock. The analyst consensus points to a rating of ‘Strong_Buy’. The target price ranges between 9 and 8 with the average target price sitting at 8.67. With the stocks previous close at 1.95 this now indicates there is a potential upside of 344.6%. There is a 50 day moving average of 1.94 while the 200 day moving average is 1.95. The market capitalisation for the company is $154m. Visit the company website at:

Soleno Therapeutics, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia and changed its name to Soleno Therapeutics in May 2017. Soleno Therapeutics was incorporated in 1999 and is headquartered in Redwood City, California.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index